Christopher Bojrab
Psychiatry · Carmel, INNPI 1689659013
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $511,173 of the $713,164 with a category attached, or 71.7%. 46 manufacturers reported payments, led by AbbVie at 30.9% of the total. Among psychiatry clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,920 payments — averaging $371.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$220K
- Axsome Therapeutics, Inc.$128K
- Teva Pharmaceuticals USA, Inc.$69K
- Neurocrine Biosciences, Inc.$62K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$48K
- Alkermes, Inc.$42K
- plus $143K from 40 others
Across 1 payment — averaging $1200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
What the payments were for
- Consulting fees$130,44618%
- Speaking & faculty fees$511,17372%
- Travel & lodging$32,2195%
- Food & beverage$38,7405%
- Education$5870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$713,164 in reported general payments places this provider in the 95th percentile of 514 psychiatry providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 23 | $330,159 |
| IngrezzaValbenazine Tosylate | 33 | $295,099 |
| VraylarCariprazine Hcl | 53 | $76,082 |
| CaplytaLumateperone Tosylate | 40 | $68,147 |
| TrintellixVortioxetine Hydrobromide | 48 | $31,625 |
| AuvelityDextromethorphan Hbr/Bupropion | 23 | $25,099 |
| SaphrisAsenapine Maleate | 14 | $17,379 |
| Aripiprazole | 68 | $16,673 |
| QuliptaAtogepant | 12 | $14,499 |
| Vilazodone Hcl | 83 | $10,540 |
| Armodafinil | 87 | $9,702 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,171 |
| Tiagabine Hcl | 11 | $7,399 |
| Bupropion XlBupropion Hcl | 249 | $7,391 |
| DayvigoLemborexant | 17 | $6,883 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $69,281 | $330,15923 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $62,492 | $295,09933 claims |
| AbbVieVraylar, Saphris, Qulipta | $220,491 | $107,96079 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $48,190 | $68,14740 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $7,929 | $31,62548 claims |
| Axsome Therapeutics, Inc.Auvelity | $127,663 | $25,09923 claims |
| Eisai Inc.Dayvigo | $7,938 | $6,88317 claims |
| Lilly USA, LLCOlanzapine | $3,292 | $1,69852 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in Carmel
- Steven PaulCarmel$2.9M
- Michael DetkeCarmel$14K
- Michael WebberCarmel$9K
- Tyler FlaninghamCarmel$7K
- Jay FawverAngola$1.4M
- Suhayl NasrMichigan City$739K
- Joseph FanelliMunster$443K
- Eric JaggersJeffersonville$260K
- Larry LambertsonFort Wayne$208K
- Louis CadyNewburgh$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.